Pipeline Watch: Phase III Readouts For SER-109, Etrolizumab, Nivolumab
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Pipeline Watch: Phase III Starts In COVID-19, Bladder Cancer, Demodex Blepharitis
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.